Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01175343 | RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT03163979 | Individualized Precise Radiotherapy With the Guidance of Radiosensitivity of Locally Advanced Cervical Cancer(PROGRAMMA) | unknown | Phase 2 / Phase 3 | 300 | Nanjing Medical UniversityOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00097019 | A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed | completed | Phase 2 | 53 | Genentech, Inc.INDUSTRY | 0 | May 16, 2017 | clinicaltrials |
| NCT02417753 | AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | May 15, 2017 | clinicaltrials |
| NCT01068509 | Ovarian Cancer Vaccine for Patients in Remission | completed | Phase 2 | 63 | Prima BioMed LtdINDUSTRY | 2 | May 11, 2017 | clinicaltrials |
| NCT01276548 | A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer(GPMOC202) | completed | Phase 2 | 102 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | May 9, 2017 | clinicaltrials |
| NCT00157573 | GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer | completed | Phase 2 | 72 | Massachusetts General HospitalOTHER | 0 | May 8, 2017 | clinicaltrials |
| NCT00603460 | DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of PennsylvaniaOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT00879359 | Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer | completed | Phase 2 | 15 | The Cleveland ClinicOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01306032 | Phase II ABT-888 With Cyclophosphamide | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 2 | Apr 26, 2017 | clinicaltrials |
| NCT01504308 | Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids(SOFIA) | terminated | Phase 2 / Phase 3 | 49 | Philips HealthcareINDUSTRY | 3 | Apr 5, 2017 | clinicaltrials |
| NCT00738699 | An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer(FAR-122) | terminated | Phase 2 | 415 | MorphotekINDUSTRY | 6 | Mar 30, 2017 | clinicaltrials |
| NCT00545792 | Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | completed | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01659554 | A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers(HIPEC) | terminated | Phase 2 | 4 | Columbia UniversityOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00321932 | Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | University of MinnesotaOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00058552 | A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer | completed | Phase 2 | 129 | Genentech, Inc.INDUSTRY | 0 | Mar 8, 2017 | clinicaltrials |
| NCT00523380 | Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer | completed | Phase 2 | 10 | Novo Nordisk A/SINDUSTRY | 2 | Mar 1, 2017 | clinicaltrials |
| NCT00002931 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer | completed | Phase 2 | 48 | City of Hope Medical CenterOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01137071 | Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer | terminated | Phase 2 | 29 | Recepta BiopharmaINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00158379 | Taxol Carboplatin and Erythropoetin | completed | Phase 2 | 105 | North Eastern German Society of Gynaecological OncologyOTHER | 0 | Feb 6, 2017 | clinicaltrials |
| NCT00584857 | A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer | completed | Phase 2 | 30 | University of Alabama at BirminghamOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT00584909 | A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus | terminated | Phase 2 | 13 | University of Alabama at BirminghamOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT02199418 | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer(SHPD001) | completed | Phase 2 | 132 | RenJi HospitalOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT00003657 | High-dose ICE With Amifostine | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00073541 | A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer | completed | Phase 2 | 38 | EMD SeronoINDUSTRY | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | terminated | Phase 2 | 1 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT00559377 | FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2016 | clinicaltrials |
| NCT00872989 | S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 129 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 19, 2016 | clinicaltrials |
| NCT01669226 | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer(AICE) | completed | Phase 2 | 215 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00452920 | Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of MiamiOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT01521143 | Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment(CANVAS) | terminated | Phase 2 | 91 | Prima BioMed LtdINDUSTRY | 2 | Dec 14, 2016 | clinicaltrials |
| NCT02990728 | Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer | unknown | Phase 2 | 120 | Chang Gung Memorial HospitalOTHER | 0 | Dec 13, 2016 | clinicaltrials |
| NCT00031629 | Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00314678 | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer | completed | Phase 2 | 40 | John P. FruehaufOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT00179712 | Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | completed | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT00171808 | Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer(deFEND) | completed | Phase 2 | 26 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT00744718 | Bevacizumab and Carboplatin for Patients With Ovarian Cancer | completed | Phase 2 | 73 | Vejle HospitalOTHER | 1 | Nov 16, 2016 | clinicaltrials |
| NCT01061606 | Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2016 | clinicaltrials |
| NCT02017353 | Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma | completed | Phase 2 | 7 | University Hospital, GasthuisbergOTHER | 1 | Oct 25, 2016 | clinicaltrials |
| NCT02562729 | Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer | completed | Phase 2 | 62 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Oct 14, 2016 | clinicaltrials |
| NCT01600573 | Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) | unknown | Phase 1 / Phase 2 | 68 | JSehouliOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT00862836 | Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)(ZACFAST) | terminated | Phase 1 / Phase 2 | 15 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Oct 10, 2016 | clinicaltrials |
| NCT01630018 | Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial | completed | Phase 2 | 141 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Sep 22, 2016 | clinicaltrials |
| NCT02244502 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | unknown | Phase 1 / Phase 2 | 31 | NovoCure Ltd.INDUSTRY | 4 | Sep 21, 2016 | clinicaltrials |
| NCT02560571 | Pre-operative Studies for Prediction of Lymph Nodes Involvement in Endometrial Cancer Patients | unknown | Phase 2 | 200 | Meir Medical CenterOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT01031381 | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer(RADBEV) | completed | Phase 2 | 50 | University of PittsburghOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT02042495 | Endometrial Cancer Biomarker Changes Following Exposure to Metformin | withdrawn | Phase 2 | 0 | Jewish General HospitalOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT00590967 | A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy | terminated | Phase 2 | 69 | Washington University School of MedicineOTHER | 1 | Aug 29, 2016 | clinicaltrials |
Data updated 24 days agoSource updated May 24, 2017source: clinicaltrials